About the Company
We do not have any company description for Arcellx, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Arcellx, Inc.
Arcellx, Inc. Reports Increased Losses Amid Rising R&D Costs
Arcellx, Inc. ( ($ACLX) ) has released its Q2 earnings. Here is a breakdown of the information Arcellx, Inc. presented to its investors. Arcellx, ...
Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates
Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $1.03. This compares to a loss of $0.51 per share a year ago. These figures are ...
Arcellx Inc’s BCMA CAR-T Therapy Shows Promising Efficacy and Safety ...
Sami Corwin has given his Buy rating due to a combination of factors demonstrating Arcellx Inc’s promising clinical data and safety profile. The interim results from the iMMagine-1 study at the ...
Arcellx Inc’s Potential in CAR-T Therapies: Efficacy, Safety, and ...
Analyst John Newman from Canaccord Genuity maintained a Buy rating on Arcellx Inc (ACLX – Research Report) and keeping the price target at $121.00. John Newman’s rating is based on several ...
Arcellx, Inc. (ACLX): Among Takeover Rumors Hedge Funds Are Buying
Arcellx, Inc. (NASDAQ:ACLX) holds strong data from its Phase II iMMagine-1 trial for treating relapsed or refractory multiple myeloma patients, making the company a notable target for takeover.
Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of ...
Investor Contact: Myesha Lacy Arcellx, Inc. ir@arcellx.com 510-418-2412 Media Contact: Andrea Cohen Sam Brown Inc. andreacohen@sambrown.com 917-209-7163 ...
Wall Street Analysts Believe Arcellx, Inc. (ACLX) Could Rally ... - Nasdaq
Shares of Arcellx, Inc. (ACLX) have gained 7% over the past four weeks to close the last trading session at $37.40, but there could still be a solid upside left in the stock if short-term price ...
Arcellx, Inc.: Trying To Build A Better Myeloma Cell Therapy
Arcellx, Inc.: Trying To Build A Better Myeloma Cell Therapy Jan. 16, 2025 6:41 AM ET Arcellx, Inc. (ACLX) Stock ACLX 2 Comments Galzus Research 2.37K Follower s Play (9min) ...
Why Is Blood Cancer Focused Arcellx Stock Trading Higher Today?
Arcellx Inc (NASDAQ: ACLX) announced that new clinical data from its Phase 1 study of CART-ddBCMA in patients with relapsed or refractory multiple myeloma will be presented at the 65th American ...
Arcellx, Inc. (ACLX) Q4 Earnings and Revenues Surpass Estimates
Arcellx, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $63.15 million for the quarter ended December 2023, surpassing the Zacks Consensus Estimate ...
Similar Companies
Loading the latest forecasts...